Sagent Pharma Launches Nafcillin for Injection, USP
Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT) today announced the launch of Nafcillin for Injection, USP, in two vial presentations and one pharmacy bulk package bottle; all three are latex-free and preservative-free. According to IMS, for the 12 months ending September 2012, the US market for Nafcillin approximated $62 million. As with all products in Sagent's portfolio, Nafcillin features the Company's PreventIV Measures^SM packaging and labeling, designed to help reduce medication errors.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.